RISK ASSESSMENT OF THE PRESENCE OF SILENT MYOCARDIAL ISCHEMIA IN TYPE 2 DIABETIC PATIENTS
https://doi.org/10.21886/2219-8075-2013-1-16-19
Abstract
Purpose: testing in clinical practice a mathematical model of risk assessment of the presence of silent myocardial ischemia (SMI) in type 2 diabetic patients.
Material and Methods: 55 type 2 diabetic patients have been studied; among them 26 (47,27%) men and 29 (52,73%) women, mean age – 57,79 ± 8,39 years, diabetes duration – 9,65 ± 6,41 years. Identified 11 parameters included in the model. Calculated and assessed the presence of factor SMI. To verify the diagnosis, all patients completed ECG monitoring with mandatory achievement of submaximal heart rate.
Results: Higher risk of having SMI was detected in 14 (25.45%) patients, low risk - in 41 (74.54%). SMI was diagnosed in 10 (71.43%) patients at high risk. In patients at low risk SIM was not found. Thus, the sensitivity of the model was 100%, specificity - 91%, the positive predictive value - 71%, and the negative - 100%.
Conclusions: This mathematical model assesses the risk of having a SMI in type 2 diabetic patients and can be used in actual practice to optimize early detection of this disease.
About the Authors
N. I. Volkova
The Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine № 3,
29, Nahichevansky st., Rostov-on-Don, 344022J. A. Sorokina
The Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine № 3,
29, Nahichevansky st., Rostov-on-Don, 344022A. V. Kharakhashyan
The Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine № 3,
29, Nahichevansky st., Rostov-on-Don, 344022L. J. Shabanova
The Rostov State Medical University
Russian Federation
Russian Federation
Department of Internal Medicine № 3,
29, Nahichevansky st., Rostov-on-Don, 344022References
1. IDF Diabetes Atlas. – 5 th ed. – 2011.
2. Демидова Т.Ю. Атеросклероз и сахарный диабет типа 2: механизмы и управление // CardioСоматика. – 2011. – № 2. – С.12-20.
3. Rydén L., Standl E., Bartnik M. et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary // European Heart Journal. – 2007. – Vol. 28 – № 1. – Р. 88–136.
4. Gutterman D.D. Silent myocardial ischemia // Circ. J. – 2009. – Vol. 73. –№ 5. –Р.785 – 797.
5. Cosson E., Nguyen M.T., Chanu B. et al. Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients // Diabetes Care. – 2011. – Vol. 34. – Р.2101–2107.
6. Волкова Н.И. Харахашян А.В. Сорокина Ю.А. Давиденко И.Ю. Стратификация больных сахарным диабетом 2 типа по риску развития безболевой ишемии миокарда // Сахарный диабет. – 2012. – № 1. – С.19–24.
7. Оганов Р.Г., Поздняков Ю.М., Акчурин Р.С. и др., Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр) // Кардиоваскулярная терапия и профилактика. – 2008. – Т. 7. – № 6. Прил. 4. – С. 5–25.
8. Upchurch C.T., Barrett E.J. Clinical review: Screening for coronary artery disease in type 2 diabetes. // J. Clin. Endocrinol. Metab. – 2012. – Vol. 97. – № 5. – Р.1434-1442.
9. American Diabetes Association. Standards of Medical Care in Diabetes – 2010 (Position Statement) // Diabetes Care. – 2010. – Vol. 33(Suppl). – Р. S4–S36.
10. De Berardis G., Lucisano G., D’Ettorre А. et al. Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes // JAMA. – 2012. – Vol. 307. – № 21. – Р. 2286-2294.
Review
For citations:
Volkova N.I., Sorokina J.A., Kharakhashyan A.V., Shabanova L.J. RISK ASSESSMENT OF THE PRESENCE OF SILENT MYOCARDIAL ISCHEMIA IN TYPE 2 DIABETIC PATIENTS. Medical Herald of the South of Russia. 2013;(1):16-19. (In Russ.) https://doi.org/10.21886/2219-8075-2013-1-16-19
Views:
396
Email this article 